Avodart Dutasteride 0.5mg 30-90 capsules

Avodart Composition
active ingredient: dutasteride;

1 capsule contains dutasteride 0.5 mg;

excipients: caprylic / capric acid monodiglycerides, butylhydroxytoluene (E 321);

capsule shell: gelatin, glycerin, titanium dioxide (E 171), iron oxide yellow (E 172), medium chain triglycerides and lecithin.

Pharmacotherapeutic group
Drugs used in benign prostatic hyperplasia. Testosterone-5a-reductase inhibitors. Code ATX G04C B02.

Indications
Treatment of symptoms of moderate and severe benign prostatic hyperplasia; reducing the risk of acute urinary retention and the need for surgical intervention in patients with symptoms of moderate and severe benign prostatic hyperplasia.

Dosage and administration
Avodart can be given as monotherapy or in combination with the alpha-blocker tamsulosin (0.4 mg).

Adult men (including elderly patients)

The recommended dose is 1 capsule (0.5 mg) per day orally. The capsule should be swallowed whole, not opened or chewed, as contact with the contents of the capsule may irritate the oral and pharyngeal mucosa.

Can be taken with or without food.

Despite the fact that relief from taking the drug can be observed at an early stage, for an objective assessment of the effectiveness of treatment, it should be continued for at least 6 months.

kidney failure

The pharmacokinetics of dutasteride in patients with renal insufficiency has not been studied, therefore, patients with severe renal insufficiency should be prescribed with caution.

Liver failure

The pharmacokinetics of dutasteride in patients with hepatic insufficiency has not been studied, therefore, caution should be used in mild to moderate hepatic insufficiency. The drug is contraindicated in patients with severe hepatic insufficiency.